Emergent Biosolutions has announced the selection of its spin-off company’s board of directors.
The spin-off company, Aptevo Therapeutics Inc., was announced by the Emergent in August. According to an earlier report from Bio Prep Watch, the company will be focused on therapeutics development in oncology and hematology.
“The selection of the board of directors for Aptevo Therapeutics is an important milestone as we advance towards completing our separation into two independent, publicly traded companies,” Daniel Abdun-Nabi, president and CEO of Emergent BioSolutions, said. “Aptevo Therapeutics will benefit from the expertise of continuing board members as well as the fresh perspectives that the new directors will bring to pursue Aptevo’s mission of providing novel oncology and hematology therapeutics to meaningfully improve patients’ lives.”
The board consists of Marvin White, Fuad El-Hibri, Daniel Abdun-Nabi, Dr. John Niederhuber, Barbara Kunz, Zsolt Harsanyi and Grady Grant III.
The company notes that White will also serve as Aptevo’s CEO. Members of the board that are associated with Emergent include Abdun-Nabi, El-Hibri and Harsanyi.
Emergent Biosolutions is focused on the development of medical countermeasures against biological and chemical threats.